QOP
AXSM icon

Quinn Opportunity Partners’s Axsome Therapeutics AXSM Stock Holding History

Quinn Opportunity Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,000
Closed -$231K – 202
2021
Q3 		$231K Hold
7,000
– – 0.01% 228
2021
Q2 		$472K Hold
7,000
– – 0.03% 182
2021
Q1 		$396K Hold
7,000
– – 0.03% 204
2020
Q4 		$570K Hold
7,000
– – 0.05% 159
2020
Q3 		$499K Sell
7,000
-2,000
-22% -$156K 0.05% 144
2020
Q2 		$741K Buy
+9,000
New +$693K 0.09% 113

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quinn Opportunity Partners's AXSM Position: Q4 2021 in Review

Quinn Opportunity Partners sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 7,000 shares — an estimated $231K sold.

Quinn Opportunity Partners first reported a position in AXSM in Q2 2020 and held it in 6 quarters. The position peaked at $741K in Q2 2020. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

  • Quinn Opportunity Partners reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Quinn Opportunity Partners sold 7,000 Axsome Therapeutics shares in Q4 2021, an estimated $231K.
  • Quinn Opportunity Partners first reported a position in Axsome Therapeutics in Q2 2020 and held it in 6 quarters.
  • Quinn Opportunity Partners's Axsome Therapeutics position peaked at $741K in Q2 2020.
  • 167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on Quinn Opportunity Partners's 13F filing for Q4 2021, filed 14 Feb 2022.